Moreover, a meta-analysis by Huthmacher et al. [62], which compared patients with T2DM that were treated with short- or long-acting GLP-1 RAs and insulin versus only insulin, reported a higher percentage of ARs, such as nausea, vomiting, diarrhea, and hypoglycemia in the GLP-1 RA and insulin groups. This evidence concerns the gene GLP1R and Hypoglycemia.